FENCHealthcare · BiotechnologyFENC Stock Forecast: Fennec Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 6 Wall Street analysts covering Fennec Pharmaceuticals, Inc. hold a median 12-month price target of $18 — +80.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 15 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
FENC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Fennec Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (88): Sales and profits are climbing, and climbing faster than before.
Accruals (18): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
FENC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on FENC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +80.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $16 |
| 12 Aug 2026 | B. Riley Securities | Reiterates | Buy | — |
| 12 Aug 2026 | Wedbush | Maintains | Outperform | — |
| 22 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Apr 2026 | Wedbush | Reiterates | Outperform | — |
| 9 Jan 2026 | Piper Sandler | Initiates | Overweight | — |
| 21 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2025 | Craig-Hallum | Maintains | Buy | — |
| 20 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2025 | Craig-Hallum | Maintains | Buy | — |
| 11 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Aug 2024 | Craig-Hallum | Maintains | Buy | — |
| 15 May 2024 | Craig-Hallum | Maintains | Buy | — |
| 15 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Mar 2024 | Craig-Hallum | Maintains | Buy | — |
| 4 Aug 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 21 June 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FENC appears on the weeks it earns a place.
FENC vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 16 Oct 2026, Fennec Pharmaceuticals, Inc. returned +15.5% against +16.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
FENC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Fennec Pharmaceuticals, Inc. (FENC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 60.4×
- Price / sales
- 6.1×
- Price / book
- 8.5×
- EV / EBITDA
- −315.0×
Cheaper than 12% of US stocks
Cheaper than 20% of US stocks
Cheaper than 10% of US stocks
Cheaper than 98% of US stocks
- Revenue growth (YoY)
- 85.2%
- Earnings growth (YoY)
- 85.2%
- Gross margin
- 96.0%
- Operating margin
- 9.7%
- Net margin
- −5.5%
Higher than 91% of US stocks
Higher than 82% of US stocks
Higher than 98% of US stocks
Higher than 64% of US stocks
Higher than 23% of US stocks
- Return on equity
- −18.6%
- Return on assets
- −1.2%
- Dividend yield
- 0.0%
Higher than 32% of US stocks
Higher than 39% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Fennec Pharmaceuticals, Inc. (FENC) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Fennec Pharmaceuticals, Inc. has a market value of $362.9M and an enterprise value of $321.7M.
Revenue in the twelve months to 30 June 2026: $59.2M. The latest quarter grew 85.2% year on year.
Net income over the same four quarters: −$3.3M, a −5.5% net margin.
Diluted earnings per share, trailing twelve months: $−0.13.
Free cash flow in the twelve months to 30 June 2026: −$2.0M.
Trailing P/E: 60.4×; forward P/E: 10.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Fennec Pharmaceuticals, Inc. employs 32 people — $1.9M of revenue per employee.
Data provided by Twelve Data
FENC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Fennec Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about FENC stock
What is the FENC stock price forecast for 2026-2027?
The 6 Wall Street analysts covering Fennec Pharmaceuticals, Inc. have a median 12-month price target of $18, with estimates ranging from $16 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is FENC stock a buy right now?
Of the 6 analysts covering Fennec Pharmaceuticals, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Fennec Pharmaceuticals, Inc. 94 out of 100 across roughly 4,600 US stocks as at 15 Oct 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank FENC?
As at 15 Oct 2026, Fennec Pharmaceuticals, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (88 of 100).
Will FENC stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies +80.4% from the last close, and Ticker Nerd's factor model ranks Fennec Pharmaceuticals, Inc. 94 out of 100 as at 15 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the FENC stock forecast for 2030?
No analyst covering Fennec Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FENC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $20 over the next 12 months.
How has FENC stock performed over the past year?
Fennec Pharmaceuticals, Inc. returned +15.5% over the 12 months to 16 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Fennec Pharmaceuticals, Inc. do?
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments that address ototoxicity, a form of hearing damage associated with certain cancer therapies.
About Fennec Pharmaceuticals, Inc.
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments that address ototoxicity, a form of hearing damage associated with certain cancer therapies. Its lead product, PEDMARK, is designed to reduce the risk of platinum-induced hearing loss in pediatric patients receiving cisplatin-based chemotherapy. The company operates in the biotechnology and oncology supportive-care markets, serving hospitals, pediatric oncology specialists, and healthcare providers involved in cancer treatment. Based in Research Triangle Park, North Carolina, Fennec Pharmaceuticals is positioned as a commercial-stage company centered on a targeted therapy that supports quality of care for children undergoing chemotherapy.
CEO Mr. Jeffrey S. Hackman · 32 employees · United States · https://fennecpharma.com